MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), today announced a strategic collaboration with Navidence to help research organizations transform rapidly expanding healthcare data into clear, actionable real-world evidence.
What This Collaboration Means for the Pharma Market
Pharmaceutical companies face growing pressure to integrate high-quality RWD for regulatory submissions, post-market surveillance, and AI model training. Navidence’s platform enables precise definition of health data needs via Computable Operational Definitions (CODefs)—standardized, executable queries that translate complex study criteria (e.g., patient cohorts by diagnosis, treatment, or outcome) into consistent, computable form across datasets.
This collaboration integrates Navidence’s CODefs with the OneMedNet iRWD™ platform powered by Palantir Foundry.
Key integration elements of the collaboration include:
OneMedNet incorporating Navidence CODefs, to enable consistent cohort, endpoint, and criteria definitions.Navidence being integrated with the OneMedNet iRWD™ platform for life sciences, to enable rapid discovery of fit-for-purpose multimodal datasets, streamlining study design regulatory / commercial evidence generation. Key Potential Benefits of the Collaboration to Our Products and Stakeholders
Efficiency Gains: Align CODefs with available RWD in near real-time to accelerate study ideation-to-execution and reduce mismatches / rework.Cost Savings: Expected to enable precise data matching to avoid over-procuring data sets or pursuing infeasible studies, optimizing R&D budgets.Regulatory and Compliance Edge: Combine OneMedNet’s de-identification expertise and Navidence’s standardized definitions to better meet FDA, EMA, and payer requirements for RWE.Innovation in Therapeutic Areas: Particularly valuable in complex fields like precision medicine, where imaging RWD (e.g., MRIs, CT scans) combined with CODefs can reveal nuanced insights into disease progression or treatment efficacy. Expanding Commercial Opportunity
Real-World Data has long been available, but missing efficient, standardized, and scalable access to Real-World Data.
This collaboration is intended to directly advance OneMedNet’s life sciences strategy by addressing core industry demands of faster, more precise and usable data for pharmaceutical and CRO customers, along with expanded opportunities in the rapidly growing RWD market (valued at approximately $1.88 billion in 2025 and projected to reach $6.37 billion by 2034 at 14.54% CAGR),1 enabling access to precisely defined, fit for purpose datasets across:
Drug development and Life sciences researchAI model training and validationHealth economics and outcomes research (HEOR)Regulatory-grade evidence generationValue-based healthcare analytics
As regulators and payers increasingly require robust real-world evidence, we believe that combining large-scale multimodal data infrastructure with computable definitions positions both companies—and their customers—at the forefront of data transformation.
“Healthcare organizations today have access to more data than ever before and turning that data into reliable evidence requires both scale and precision,” said Aaron Green, CEO & President of OneMedNet. “By combining OneMedNet’s multimodal real-world data platform with Navidence’s computable definitions, we can help researchers identify the right data faster and design studies that deliver high impact evidence.”
“Computable Operational Definitions (CODefs) provide the foundation for consistent and reproducible research independent of the data source,” said Aaron Kamauu, Navidence. “By integrating our content with the OneMedNet iRWD™ platform, researchers can discover precisely defined cohorts and datasets that accelerate study development and improve consistency across clinical research.”
https://www.precedenceresearch.com/real-world-data-rwd-market About Navidence Inc.
Navidence is a technology company that helps healthcare and life sciences organizations design and assess the use of real-world data in clinical research studies and clinical trials. Through its platform and Computable Operational Definitions (CODefs), Navidence enables consistent, transparent, and reproducible analysis of complex real-world data to support smarter research and better patient outcomes. To learn more about Navidence, visit www.navidence.com and follow us on LinkedIn.
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our products, plans and strategies (including the expected benefits of the collaboration with Navidence), and our ability to achieve our operational strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]
MINNEAPOLIS, April 01, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), is pleased to announce that Inka Health, a wholly-owned subsidiary of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has entered into a collaboration with OneMedNet Inc., under which Onco-Innovations and Inka Health will have access to OneMedNet’s iRWD™ platform— powered by Palantir (PLTR) Foundry— providing it access to U.S. real-world oncology data. The agreement is intended to accelerate development timelines, reduce clinical and regulatory risk, and strengthen evidence generation for Onco-Innovations’ proprietary PNKP Inhibitor Technology targeting PTEN/SHP1-deficient cancers.
Under the agreement, Inka Health is gaining access to OneMedNet’s iRWD™ platform through a selective pilot program following technical evaluation and qualification. The collaboration will initially focus on applying real-world data and advanced analytics to support Onco’s PNKP Inhibitor Technology’s development strategy, including patient responder identification, indication expansion beyond advanced metastatic colorectal cancer, and complementary evidence generation to inform clinical and regulatory decision-making. Inka Health also intends to use OneMedNet’s iRWD™ platform to improve and further develop the core model of SynoGraph™, its causal-inference based AI platform that aims to predict the success and safety of potential new cancer treatments by analyzing multimodal medical data.
Importantly, this engagement reflects the original architectural intent of the iRWD™ platform: to enable rapid identification and characterization of rare and molecularly defined patient populations at scale. By combining multi-modal data, longitudinal clinical context, and AI-augmented search capabilities, the platform is purpose-built to locate hard-to-find cohorts, —such as PTEN/SHP1-deficient tumors—, and accelerate innovation in areas where traditional trial recruitment and evidence development can be challenging.
“This collaboration demonstrates exactly what our iRWD™ platform was designed to do—find and characterize rare, high-value patient populations to accelerate innovation,” said Aaron Green, CEO & President of OneMedNet. “By bringing together regulatory-grade real-world data, multi-modal clinical depth, and Palantir-powered AI, we can help oncology innovators de-risk development, move faster, and generate meaningful evidence in complex disease segments.”
“Access to high-quality U.S. oncology real-world data is a critical enabler for PNKP Inhibitor Technology,” said Thomas O’Shaunghnessy, CEO of Onco-Innovations. “This collaboration allows us to better understand real-world patient populations with PTEN/SHP1-deficient tumors, identify potential responders, and explore additional indications—, helping us de-risk development while improving capital efficiency for shareholders.”
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our products, plans and strategies, and our ability to achieve our operational strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]
MINNEAPOLIS, April 06, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), highlights its 2025 results, with robust revenue growth from the prior year, a strengthened balance sheet, and continued commercial momentum driven by Palantir Foundry enabled conversational search on Real-Time medical data from OneMedNet’s rapidly growing network.
2025 Financial Highlights:
RWD Revenue Growth: RWD revenue increased 329% year-over-year, rising from $292,000 in 2024 to $1,254,000 in 2025, reflecting strong market demand and increased commercial traction. Fourth Quarter Revenue Acceleration: Our work towards building and executing upon our strategy came together during the quarter ended December 31, 2025 with revenue surging to over $890,000. Bookings Momentum: Revenue growth is beginning to align with previously disclosed increases in bookings, reinforcing the Company’s transition toward a scalable, subscription-based model. Total Liabilities Reduced by 74%: Total liabilities decreased from $19.7 million at December 31, 2024 to $5.1 million at December 31, 2025.Driven by a combination of negotiated settlements and debt-to-equity conversions. Equity Position Improved: Shareholder deficit substantially reduced from $(16.0) million to $(3.0) million.
Building upon next commercial phase momentum:
Following its February 2026 announcement, OneMedNet entered a new phase of commercial execution centered on its AI-driven iRWD™ platform powered by Palantir Foundry, with the following commercial highlights: 2 Pilot Customers in contracting.4 Additional customers expected in the second and third quarter of 2026, each representing a seven-figure subscription revenue potential over the term of the contract.Advanced stage pipeline of additional multi-year subscription opportunities. Early Verbal Customer Feedback of the OneMedNet Platform: Cohort discovery timelines reduced from weeks to minutes - Significant improvements in feasibility analysis and dataset precision.Ability to query over a billion data points with results returned in seconds. Platform Scale and Network Expansion Outlook: OneMedNet accelerates its provider network expansion and overall data scale, enabling the Company to fulfill additional orders and deliver greater value to subscription customers.Projected 4x growth in the platform by the end of 2026. “Our 2025 performance marks a pivotal turning point for OneMedNet,” said Aaron Green, CEO & President. “We have successfully sunset our BEAM solution along with the expenses associated with it, allowing us to focus fully on our Real-World Data business achieving meaningful revenue acceleration, dramatically improving our balance sheet, and launching the next generation of our platform. We believe the early response from customers validates our strategy — delivering real-world data with the speed, scale, and intelligence required to power modern healthcare innovation. Looking ahead to 2026, we will continue to build and execute on this strategy and expect revenues to grow substantially.”
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our products, plans and strategies, our expected growth in the business, and our ability to achieve our operational strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
MINNEAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), today announced that its OneMedNet iRWD™ Platform, built on Palantir Foundry, is now live and fully operational. This major commercialization milestone delivers searchable access to billions of records across 80 million patient journeys in seconds, transforming how life sciences organizations access and analyze multi-modal clinical data at unprecedented scale and speed.
Key Commercial Milestones of iRWD™ Platform:
OneMedNet iRWD™ Platform Now Live on Palantir Foundry~70% increase in OneMedNet network, to 80 million patients and 251 million studies Creating what we believe is the industry's largest network of curated, multi-modal Real-World Data Creates access to approximately 47 million tokenized patients via Datavant Enables seamless linkage to complementary datasets including genomics, claims, and mortality data for deeper longitudinal insights Two new customers contracted for iRWD™ Platform "The integration of our iRWD™ platform with Palantir Foundry marks a transformative step for OneMedNet. Our subscription customers can now find the data they need in seconds — unlocking a new phase of commercial execution and significantly enhancing our ability to deliver high-value, decision-grade data. We are now actively converting a robust pipeline into subscription-based customers with meaningful annual recurring revenue potential." said Aaron Green, President & CEO of OneMedNet. "Most importantly, we've unlocked the patients our customers require: about 80 million patients on the network and 47 million tokenized patients on Datavant. We previously outlined this strategy, and we've now executed on it. By combining Palantir's powerful ontology and analytics capabilities with Datavant's tokenized linkage, we can deliver longitudinally connected, multimodal datasets that accelerate foundational AI model development and create durable, long-term value."
With the Palantir-powered iRWD™ platform now live and fully searchable, OneMedNet is executing its strategy of securing high-margin, annual recurring revenue (ARR) subscriptions. The Company believes the combination of the new platform capabilities and an expanding customer pipeline positions the Company to convert growing interest into meaningful revenue opportunities.
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the expected benefits and demand to be driven by the integration of the completed iRWD™ platform, and statements generally about our products, plans and strategies, our expected growth in the business, and our ability to achieve our operational strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]
OneMedNet Corporation (NASDAQ:ONMD – Get Free Report) Director Thomas Kosasa purchased 280,898 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was acquired at an average price of $0.89 per share, with a total value of $249,999.22. Following the completion of the transaction, the director owned 16,661,327 shares in the company, valued at approximately $14,828,581.03. This trade represents a 1.71% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Thomas Kosasa also recently made the following trade(s):
On Friday, February 6th, Thomas Kosasa purchased 595,238 shares of OneMedNet stock. The stock was acquired at an average price of $0.84 per share, with a total value of $499,999.92. OneMedNet Price Performance Shares of NASDAQ ONMD opened at $1.10 on Monday. OneMedNet Corporation has a twelve month low of $0.31 and a twelve month high of $4.22. The firm has a fifty day simple moving average of $0.80 and a 200 day simple moving average of $1.23. The company has a market capitalization of $57.42 million, a PE ratio of -15.71 and a beta of 1.16.
OneMedNet (NASDAQ:ONMD – Get Free Report) last released its earnings results on Monday, March 30th. The company reported ($0.07) earnings per share (EPS) for the quarter. The company had revenue of $0.89 million for the quarter.
Analyst Upgrades and Downgrades Separately, Weiss Ratings restated a “sell (d-)” rating on shares of OneMedNet in a report on Friday, January 9th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.
Check Out Our Latest Research Report on OneMedNet
Hedge Funds Weigh In On OneMedNet Several hedge funds and other institutional investors have recently bought and sold shares of ONMD. Exencial Wealth Advisors LLC lifted its holdings in OneMedNet by 141.3% in the third quarter. Exencial Wealth Advisors LLC now owns 3,599,460 shares of the company’s stock valued at $3,923,000 after buying an additional 2,107,598 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in OneMedNet in the third quarter valued at $25,000. Correct Capital Wealth Management acquired a new stake in OneMedNet in the third quarter worth $4,910,000. HRT Financial LP acquired a new stake in OneMedNet in the fourth quarter worth $32,000. Finally, Jane Street Group LLC acquired a new stake in OneMedNet in the fourth quarter worth $119,000. Institutional investors and hedge funds own 0.95% of the company’s stock.
About OneMedNet (Get Free Report)
OneMedNet Corporation provides clinical imaging solutions. It offers iRWD, a solution that utilizes AI to securely de-identify, search, and curate imaging data for its partner network consisting of medical and academic research institutions to generate progression in stages of medical research, discovery and diagnostics that span the field of life sciences. OneMedNet Corporation is based in Eden Prairie, Minnesota.
Further Reading Five stocks we like better than OneMedNet
Receive News & Ratings for OneMedNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OneMedNet and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINENVIDIA Corporation $NVDA Stock Position Increased by Diversify Advisory Services LLC
NEXT HEADLINE »United Therapeutics (NASDAQ:UTHR) CFO Sells $209,609.40 in Stock
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), today announced that its OneMedNet iRWD™ Network, has surpassed 90 million patient journeys and 270 million studies, with a healthcare partner network now exceeding 2,300 sites. The milestone represents direct progress against the strategic priorities the Company laid out to shareholders at the close of 2025, when OneMedNet identified expansion of its data network as a core pillar of long-term value creation. Today's announcement reflects the team's disciplined execution against that commitment – extending the breadth, depth, and connectivity of the network to meet accelerating demand for Real-World Data and AI foundational models.
Key Milestones:
More than 90 million patient journeys, a 12.5% increase since April 2026 in just two months, with 270 million studies available.Expanded provider network by more than 30% in less than a year, growing from approximately 1,750 to more than 2,300 healthcare partner sites.Encompasses hard to find data such as rare diseases, oncology, cardiology, and beyond.Increased specialized multi-modal data coverage across Radiology, Cardiology, EEG, ECG, and other diagnostic modalities, alongside de-identified electronic health records. “Surpassing 90 million patient journeys, 270 million studies, and 2,300 healthcare partner sites is exactly the kind of progress we told our shareholders to expect when we outlined our strategy at the end of 2025," said Aaron Green, President & CEO of OneMedNet. "Growing the network is a deliberate, central pillar of how we build durable value, and this milestone shows the team executing against that plan. Life sciences organizations, drug developers, and AI innovators increasingly require deeper, more diverse, and longitudinally connected datasets. By continuously expanding our provider partnerships and the breadth of our curated, multi-modal data, we are uniquely positioned to meet the needs of life sciences organizations, drug developers, and AI innovators — delivering durable, long-term value for our customers and shareholders."
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the achievement of our strategies, , and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
MINNEAPOLIS, June 10, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), today announced it has secured more than $3 million in new bookings to date for 2026 as of this announcement – surpassing the Company's total bookings for all of full-year 2025. The Company expects to recognize substantially all of these bookings as revenue by the end of the third quarter of 2026.
